Document Detail


Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD.
MedLine Citation:
PMID:  23303512     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: The National Institute of Mental Health Affective Disorders Workgroup identified the assessment of an individual's burden of illness as an important need. The Individual Burden of Illness Index for Depression (IBI-D) metric was developed to meet this need.
OBJECTIVE: To assess the use of the IBI-D for multidimensional assessment of treatment efficacy for depressed patients.
DESIGN, SETTING, AND PATIENTS: Complete data on depressive symptom severity, functioning, and quality of life (QOL) from depressed patients (N = 2280) at entry and exit of level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (12-week citalopram treatment) were used as the basis for calculating IBI-D and self-rating scale changes.
RESULTS: Principal component analysis of patient responses at the end of level 1 of STAR*D yielded a single principal component, IBI-D, with a nearly identical eigenvector to that previously reported. While changes in symptom severity (Quick Inventory of Depressive Symptomatology-Self Report) accounted for only 50% of the variance in changes in QOL (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form) and 47% of the variance in changes in functioning (Work and Social Adjustment Scale), changes in IBI-D captured 83% of the variance in changes in QOL and 80% in functioning, while also capturing 79% of the variance in change in symptom severity (Quick Inventory of Depressive Symptomatology-Self Report). Most importantly, the changes in IBI-D of the 36.6% of remitters who had abnormal QOL and/or functioning (mean [SD], 2.98 [0.35]) were significantly less than the changes in IBI-D of those who reported normal QOL and functioning (IBI-D = 1.97; t = 32.6; P < 10(-8)) with an effect size of a Cohen d of 2.58. In contrast, differences in symptom severity, while significant, had a Cohen d of only 0.78.
CONCLUSIONS: Remission in depressed patients, as defined by a reduction in symptom severity, does not denote normal QOL or functioning. By incorporating multidimensional patient-reported outcomes, the IBI-D provides a single measure that adequately captures the full burden of illness in depression both prior to and following treatment; therefore, it offers a more accurate metric of recovery.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00021528.
Authors:
Robert M Cohen; Jared M Greenberg; Waguih William IsHak
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  JAMA psychiatry     Volume:  70     ISSN:  2168-6238     ISO Abbreviation:  JAMA Psychiatry     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-07     Completed Date:  2013-05-02     Revised Date:  2014-01-24    
Medline Journal Info:
Nlm Unique ID:  101589550     Medline TA:  JAMA Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  343-50     Citation Subset:  AIM; IM    
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00021528
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Antidepressive Agents, Second-Generation / therapeutic use
Citalopram / therapeutic use
Clinical Trials as Topic
Cost of Illness*
Depressive Disorder, Major / drug therapy,  psychology*
Female
Humans
Male
Middle Aged
Outcome Assessment (Health Care) / methods
Psychometrics / instrumentation
Quality of Life / psychology*
Questionnaires
Self Report
Severity of Illness Index*
Grant Support
ID/Acronym/Agency:
N01MH90003/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Antidepressive Agents, Second-Generation; 0DHU5B8D6V/Citalopram
Comments/Corrections
Comment In:
JAMA Psychiatry. 2013 Dec;70(12):1375   [PMID:  24306816 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fragment Recruitment on Metabolic Pathways (FROMP): Comparative metabolic profiling of metagenomes a...
Next Document:  Immunomodulation in transfused trauma patients.